Mogrify adds Dr. Lorenz Mayr to Board of Directors and Scientific Advisory Board
7th July 2020
Mogrify and Sangamo announce collaboration and exclusive license agreement for Mogrify’s iPSC- and ESC-derived regulatory T cells
21st April 2020
Mogrify awarded $1.1M additional funding from SBRI Healthcare
28th January 2020
Mogrify wins Innovation Award and Dr. Jane Osbourn, OBE receives Lifetime Achievement Award at Scrip Awards 2019
5th December 2019
Mogrify wins Seed Stage Finance Raise of the Year at 2019 European Lifestars Awards
20th November 2019
Mogrify named ‘The One to Watch’ at Cambridge Independent Science and Technology Awards 2019
31st October 2019
Mogrify raises additional $16 million to advance its mission to transform the development of life-saving cell therapies
14th October 2019
Mogrify appoints Dr. Jane Osbourn, OBE as Chair
9th September 2019
Mogrify to host careers open day at Bio-Innovation Centre, Cambridge Science Park
16th July 2019
Mogrify strengthens team and relocates to the Bio-Innovation Centre, TusPark Cambridge
20th May 2019
Mogrify subsidiary Chondrogenix secures funding from SBRI Healthcare to advance regenerative cartilage therapy to the clinic
1st April 2019
Mogrify wins Business Weekly award for ‘Disruptive Technology’
21st March 2019
Mogrify awarded $555,000 USD (£420,000 GBP) Innovate UK funding to accelerate regenerative cell therapies
18th March 2019
Mogrify raises $3.7 million USD seed funding to accelerate its mission to transform cell therapy via direct cellular conversion
20th February 2019